TrialAmerican heart journal2026

Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial.

Matthew S Durstenfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.